Sign In
Buy ZYME
$22.86
-0.260 (-1.12%)
At Close: Jul 24, 2026
Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
09:15pm, Wednesday, 14'th Jan 2026
Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
06:00am, Monday, 12'th Jan 2026
VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip
HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth
03:59am, Monday, 12'th Jan 2026
Zymeworks delivered strong Phase 3 HERIZON-GEA-01 results for Ziihera, achieving over two years median overall survival in HER2-positive GEA. ZYME stands to receive up to $440 million in milestone pay
Zymeworks Outlines Strategic Priorities and Outlook for 2026
06:00pm, Sunday, 11'th Jan 2026
VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip
Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial
01:12pm, Wednesday, 07'th Jan 2026
Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HER2-positive stomach cancer live longer, with some treatments pushing survival beyond two years.
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of “Buy” from Analysts
01:30am, Wednesday, 07'th Jan 2026
Zymeworks Inc. (NYSE: ZYME - Get Free Report) has been given a consensus recommendation of "Buy" by the eleven ratings firms that are covering the firm, Marketbeat.com reports. Eleven research analyst
VANCOUVER, British Columbia, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip
Zymeworks (NYSE:ZYME) Insider Paul Andrew Moore Sells 20,110 Shares of Stock
05:20am, Tuesday, 06'th Jan 2026
Zymeworks Inc. (NYSE: ZYME - Get Free Report) insider Paul Andrew Moore sold 20,110 shares of the company's stock in a transaction on Monday, January 5th. The stock was sold at an average price of $25
Zymeworks (NYSE:ZYME) EVP Jeffrey Smith Sells 10,538 Shares
05:20am, Tuesday, 06'th Jan 2026
Zymeworks Inc. (NYSE: ZYME - Get Free Report) EVP Jeffrey Smith sold 10,538 shares of the company's stock in a transaction on Monday, January 5th. The shares were sold at an average price of $25.10, f
Zymeworks Inc. $ZYME Shares Purchased by Assenagon Asset Management S.A.
03:26am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. raised its stake in Zymeworks Inc. (NYSE: ZYME) by 169.2% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,326,774 share
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of “Buy” from Brokerages
01:16am, Saturday, 13'th Dec 2025
Shares of Zymeworks Inc. (NYSE: ZYME - Get Free Report) have earned an average recommendation of "Buy" from the ten brokerages that are covering the stock, Marketbeat reports. Ten investment analysts
Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
11:23pm, Wednesday, 03'rd Dec 2025
Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Zymeworks Announces Participation in Upcoming Conferences
04:05pm, Tuesday, 02'nd Dec 2025
• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera ® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a
Critical Review: Acerus Pharmaceuticals (OTCMKTS:ASPCF) vs. Zymeworks (NASDAQ:ZYME)
02:30am, Tuesday, 02'nd Dec 2025
Acerus Pharmaceuticals (OTCMKTS:ASPCF - Get Free Report) and Zymeworks (NASDAQ: ZYME - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the tw
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Monday, 24'th Nov 2025
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipe
